{ "docId": "019dd923-622c-750b-8b99-bca3fd68622d", "docSlug": "4c8fe6013c68", "documentTitle": "iRhythm Technologies, Inc. (IRTC)", "authorId": "54_Spruce_Point_Capital", "authorName": "Spruce Point Capital Management", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-18 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 12, "pageCount": 101, "prevPage": 11, "nextPage": 13, "slideType": "key_messages", "function": "diagnose_problem", "density": "dense", "nDataPoints": 0, "notes": "The slide is structured as two distinct sections: one on business headwinds and one on management credibility.", "elementsJson": [ "headline_text", "paragraph" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/12", "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d", "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-12", "components": [ { "bbox": null, "kind": "callout", "text": "We Do Not Believe iRhythm Senior Management is Credible: The FDA Actions Should Not be a Survivable Event", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-0395-748f-9565-ab118bdc86a4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.4, "w": 0.96, "x": 0.02, "y": 0.58 }, "kind": "paragraph", "text": "We believe the FDA findings are damning and that this should not be a survivable event, even if they are eventually fully remediated. The record shows a massive failure of action to address and properly report serious product safety issues. We believe management has not only violated investor trust, but the evidence presented by the FDA suggests they have also violated the Company's own Code of Conduct. We believe CEO Blackford has a particularly poor track record of forthright disclosure. Management's track record is all the more troubling when viewed in the context of their involvement with other troubled companies. We were concerned to find that nearly every company with which CEO Blackford has been associated has faced scrutiny for questionable practices. And where has the iRhythm Board been? They have adjusted executive incentive compensation to reward management for remediating the troubles they oversaw (effectively compensating them for not endangering patient safety and operating within standard regulatory guidelines) and, curiously, overseen the significant watering down of the Company's Code of Conduct. The Company's executive suite has been a revolving door for years, and we uncovered employee discontent with the actions taken by the \"Dexcom crew\". The iRhythm Board has also undergone near-complete turnover since coming public, and we are particularly troubled by the recent departure of two longtime directors and their replacement with former industry executives with questionable track records. Importantly, we note that iRhythm insiders have only a small stake in the Company (or exposure to its risks), as stock sales since the receipt of the first FDA Form 483 have totaled about half of current common ownership.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "cad84907-dbbb-489a-83e1-dbccddd7d47e", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.38, "w": 0.96, "x": 0.02, "y": 0.17 }, "kind": "paragraph", "text": "related to its CCT operations. Reimbursement issues have historically been a negative catalyst for iRhythm shares, and we see risks of continued reimbursement decreases for the Zio AT (or any future MCT product) due to decreasing service delivery costs and alternative solution costs. Importantly, most of iRhythm's recent Q2 outperformance versus expectations came from its core LTCM market, where its high market share limits continued gains, rather than oft-cited new market opportunities. Investors may have missed it, but iRhythm disclosed on its Q2 earnings call that the MCT market opportunity is smaller than assumed. iRhythm has also pitched a massive international opportunity, yet we find that growth in the UK (its largest ex-U.S. market) has been modest, and a recent reimbursement ruling in Japan was a disappointment that we believe management should have foreseen. Given historic preference for traditional Holter monitors and a lack of reimbursement, we question both the topline growth potential and profit prospects for international markets. Our analysis highlights real risks to the Company meeting 2027E revenue expectations. These headwinds are particularly concerning, as we believe the Company has a structurally unattractive margin model. We believe investors also should be concerned that the Company's regulatory issues have been accompanied by a material decrease in business and financial transparency, we believe a harbinger for future financial disappointments.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d6982e26-d5cd-4667-aeab-328a9b437f80", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.96, "x": 0.02, "y": 0.53 }, "kind": "title", "text": "We Do Not Believe iRhythm Senior Management is Credible: The FDA Actions Should Not be a Survivable Event", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fb5e102e-ee6e-476d-9ffd-7a29904e7695", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.31, "y": 0.03 }, "kind": "title", "text": "We Believe Worsening Headwinds Will Pressure Growth", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "342c46c9-eb31-41d1-9c9a-d576794ecd8a", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 24, "from": 8, "beatId": "98bf75b1-d631-41a2-8007-79b7391e3925", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Expose Contradiction", "beatSlug": null, "evidence": "The document presents various contradictions and concerns regarding iRhythm's products and practices.", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "loops": [ { "to": 20, "from": 9, "name": "The Reveal", "slug": "05-the-reveal", "bestFor": "Product launches, strategic pivots, unexpected findings", "matchId": "8bdc237c-9f95-46ed-95d1-4a4201a5a71e", "evidence": "The document presents various concerns and criticisms of iRhythm.", "position": 0, "objective": "To reveal concerns about iRhythm's products and management practices", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "confidence": 0.7, "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }